Adva-27a / Sunshine Biopharma - LARVOL DELTA

Sunshine Biopharma Reports Operating Results for the Fiscal Year Ended December 31, 2023 (ACCESSWIRE) - "The Company's two proprietary drugs in development advanced to the animal testing stage for both SBFM-PL4 targeted for SARS Coronavirus infections and K1.1 mRNA for liver cancer. IND-enabling studies of Adva-27a anticancer compound were halted in November 2023 pending further analysis of unfavorable in vitro results obtained earlier in the year."

Discontinued • Preclinical • Hepatocellular Cancer

Sunshine Biopharma Signs Research Agreement With the Jewish General Hospital to Advance the Development of Adva-27a Anticancer Compound (GlobeNewswire) - "Sunshine Biopharma Inc...today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital...located in Montreal, Quebec, Canada. The research effort will be focused on advancing the development of Sunshine Biopharma’s Adva-27a anticancer compound through the IND-enabling studies. At any time the research results become conclusive and Sunshine Biopharma wishes to proceed to conducting a Phase I clinical trial, the Jewish General Hospital is prepared to negotiating a new agreement to define the responsibilities and obligations of the parties for such Phase I clinical trial to be performed...Adva-27a had previously been shown to be effective at destroying multidrug resistant cancer cells originating from pancreatic cancer, breast cancer, small-cell lung cancer and uterine sarcoma."

Licensing / partnership • New P1 trial • Breast Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor

Sunshine Biopharma’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer Types (GlobeNewswire) - "Sunshine Biopharma Inc...announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types."

Preclinical • Oncology

Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033 (GlobeNewswire) - "Sunshine Biopharma Inc...announced that it has received a 'Notice of Allowance' from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until 2033. The Canadian Intellectual Property recently issued a Notice of Allowance for the analogous patent in Canada."

Patent • Oncology

Sunshine Biopharma Signs an Agreement with a Montreal-based Company to Advance the Development of Adva-27a Anticancer Compound (BioSpace) - "Sunshine Biopharma, Inc...today announced that it has entered into a collaboration agreement with Montreal-based company for the purposes of advancing the development of Sunshine Biopharma's anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture...It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University's Jewish General Hospital in Montreal, Canada."

Licensing / partnership • Gastrointestinal Cancer • Oncology • Pancreatic Cancer